Redifferentiation Therapy with Retinoids: Therapeutic Option for Advanced Follicular and Papillary Thyroid Carcinoma

No abstract is available for this paper.

• Publication year

  1998

• Venue

  World Journal of Surgery

• Publication date

  1998-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s002689900436PMID 9597930
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom

  2009cited by this paper
• Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results.

  2009cited by this paper
• Retinoide in der Onkologie

  2008cited by this paper
• The promoter of the human type I 5'-deiodinase gene--mapping of the transcription start site and identification of a DR+4 thyroid-hormone-responsive element.

  1997cited by this paper
• Vitamin D interferes with transactivation of the growth hormone gene by thyroid hormone and retinoic acid

  1996cited by this paper
• Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer

  1995cited by this paper
• Retinoic acid induces intercellular adhesion molecule-1 hyperexpression in human thyroid carcinoma cell lines.

  1995cited by this paper
• Thyroid hormone regulates stromelysin expression, protease secretion and the morphogenetic potential of normal polarized mammary epithelial cells.

  1995cited by this paper
• Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells.

  1994cited by this paper
• Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines.

  1994influential reference
• Expression of all-trans-retinoic acid receptor RNA in human thyroid cells.

  1994cited by this paper
• Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling.

  1994cited by this paper
• Vitamin A, differentiation and cancer.

  1994cited by this paper
• Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic, and neoplastic human thyroid tissue.

  1994cited by this paper
• 3,5,3'-Triiodothyronine stimulates retinoic acid-induced differentiation in HL-60 cells.

  1994cited by this paper
• Expression of the human TSH receptor in a human thyroid carcinoma cell line that lacks an endogenous TSH receptor: growth inhibition by cAMP.

  1993cited by this paper
• Surgical reintervention for differentiated thyroid cancer

  1993cited by this paper
• Thyroid hormone receptor can modulate retinoic acid-mediated axis formation in frog embryogenesis

  1993cited by this paper
• [Retinoids in oncology].

  1993cited by this paper
• Retinoic acid receptors: transcription factors modulating gene regulation, development, and differentiation.

  1992cited by this paper
• Alkaline phosphatase activity during differentiation of the human promyelocytic leukemia cell line, HL-60.

  1992cited by this paper
• Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity.

  1992cited by this paper
• The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR

  1991cited by this paper
• All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.

  1990cited by this paper
• Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro.

  1990cited by this paper
• Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

  1988cited by this paper
• Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

  1988cited by this paper
• Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment.

  1987cited by this paper
• Treatment of advanced squamous cell carcinoma of the skin with isotretinoin.

  1987cited by this paper
• Advances in our understanding of thyroid hormone action at the cellular level.

  1987cited by this paper
• The c-erb-A gene encodes a thyroid hormone receptor

  1986cited by this paper
• Nuclear thyroid hormone receptors in human cancer tissues.

  1986cited by this paper

• Treatment with Kinase Inhibitors Plus Myo-Inositol as Re-Differentiating Agents in Iodine-Refractory Thyroid Cancers

  2026cites this paper
• Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment

  2025cites this paper
• Enhancing radioactive iodine (RAI) incorporation in RAI-refractory differentiated thyroid cancer: current insights

  2025cites this paper
• Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.

  2023cites this paper
• The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis

  2022cites this paper
• Redifferentiation therapy-Returning to our roots in a post-kinase inhibitor world.

  2022cites this paper
• Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

  2022cites this paper
• The relationship between thyroid disorders and vitamin A.: A narrative minireview

  2022cites this paper
• Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study

  2021cites this paper
• An investigation into the dimerisation of the sodium-iodide symporter

  2019cites this paper
• Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy

  2019cites this paper
• BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer

  2018cites this paper
• Response of Retinoic Acid in Patients with Radioactive Iodine-Refractory Thyroid Cancer: A Meta-Analysis

  2018cites this paper
• 12 Differentiation Therapy in Thyroid Carcinoma

  2018cites this paper
• Vitamin A, endocrine tissues and hormones: interplay and interactions

  2017cites this paper
• Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy

  2017cites this paper
• The Thyroid Na+/I- Symporter: Molecular Characterization and Genomic Regulation

  2016cites this paper
• Effects of isotretinoin on the thyroid gland and thyroid function tests in acne patients: A preliminary study

  2016cites this paper
• Radioiodine-Refractory Thyroid Cancer: Restoring Response to Radioiodine Therapy

  2016cites this paper
• Acute and Subacute, and Riedel’s Thyroiditis

  2015cites this paper
• New Strategies for Combined Radioiodine Therapy in Refractory Thyroid Cancer

  2015cites this paper
• Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients

  2014cites this paper
• Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology

  2014cites this paper
• Guidelines for the management of thyroid cancer

  2014cites this paper
• New treatment modalities in advanced thyroid cancer.

  2012cites this paper
• Retinoids: novel immunomodulators and tumour‐suppressive agents?

  2012cites this paper
• Alpha-Lipoic Acid Decreases Iodine Uptake in the Rat Thyroid Cell Line FRTL-5

  2012cites this paper
• Redifferentiation Therapy in Thyroid Cancer

  2012cites this paper
• Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.

  2012cites this paper
• Differentiation Therapy in Thyroid Carcinoma

  2012cites this paper
• Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence

  2011cites this paper
• Molecular nuclear therapies for thyroid carcinoma.

  2011cites this paper
• Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma.

  2011cites this paper
• Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience

  2011cites this paper
• Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer

  2011cites this paper
• Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer

  2011cites this paper
• Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

  2011cites this paper
• Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma.

  2011cites this paper
• Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma

  2010cites this paper
• Proteomic approach reveals novel targets for retinoic acid-mediated therapy of thyroid carcinoma.

  2010cites this paper
• Chirurgie der Schilddrüsenkarzinome

  2009cites this paper
• The Importance of Age over Radioiodine Avidity as a Prognostic Factor in Differentiated Thyroid Carcinoma with Distant Metastases

  2009cites this paper
• Using Retinoids to Increase Radioiodine Uptake in Thyroid Cancer

  2009cites this paper
• Inhibitory effects of retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro

  2009cites this paper
• 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study

  2009cites this paper
• Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer.

  2009cites this paper
• Chapter 102 – Using Retinoids to Increase Radioiodine Uptake in Thyroid Cancer: Role as Potential Redifferentiation Agents

  2009cites this paper
• Medikamentöse Therapie endokriner Karzinome

  2009cites this paper
• The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer

  2008cites this paper
• Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma

  2008cites this paper
• The thyrotropin receptor in thyroid carcinoma

  2008cites this paper
• Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines.

  2008cites this paper
• The Comparative Effects of Gene Modulators on Thyroid-Specific Genes and Radioiodine Uptake

  2007cites this paper
• The importance of sodium/iodide symporter (NIS) for thyroid cancer management.

  2007cites this paper
• Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells.

  2007cites this paper
• Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome.

  2007cites this paper
• Use of radiopharmaceuticals for diagnosis, treatment, and follow-up of differentiated thyroid carcinoma.

  2007cites this paper
• Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake

  2007cites this paper
• Treatment of Differentiated Thyroid Carcinoma

  2007cites this paper
• 25-Hydroxyvitamin D3 1α-Hydroxylase and Vitamin D Receptor Expression in Papillary Thyroid Carcinoma

  2006cites this paper
• New molecular targeted therapies in thyroid cancer

  2006cites this paper
• Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.

  2006cites this paper
• Statins as a new therapeutic approach in dedifferentiated thyroid cancer?

  2006cites this paper
• Effect of all-trans retinoic acid and sodium butyrate in vitro and in vivo on thyroid carcinoma xenografts

  2006cites this paper
• Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment.

  2006cites this paper
• Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.

  2006cites this paper
• Capecitabine Therapy for Refractory Metastatic Thyroid Carcinoma: A Case Series

  2006cites this paper
• Chapter 7 Preclinical studies of chemotherapy for undifferentiated thyroid carcinoma

  2006cites this paper
• Perspectivas de novos tratamentos para o carcinoma tireoidiano avançado

  2006cites this paper
• Treatment with Cytotoxic Drugs

  2005cites this paper
• Alternative Strategies in the Management of De-Differentiated Thyroid Cancer

  2005cites this paper
• Chapter 20 – Recurrent Thyroid Cancer

  2005cites this paper
• [Poorly differentiated thyroid carcinomas: new therapeutic considerations].

  2005cites this paper
• Multiple Signaling Pathways Converge on β-Catenin in Thyroid Cancer

  2005cites this paper
• Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.

  2005cites this paper
• Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer.

  2005cites this paper
• Carcinoma de tireóide pouco diferenciado: novas considerações terapêuticas

  2005cites this paper
• Anaplastic Thyroid Carcinoma: A Therapeutic Dilemma

  2005cites this paper
• New Promising Therapeutic Modalities for Thyroid Cancers

  2005cites this paper
• Actualités en endocrinologie thyroïdienne

  2005cites this paper
• [Investigating patients with differentiated thyroid carcinoma and elevated serum thyroglobulin but negative whole-body scan].

  2005cites this paper
• Abordagem dos pacientes com carcinoma diferenciado de tireóide com tireoglobulina sérica elevada e pesquisa de corpo inteiro negativa

  2005cites this paper
• All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.

  2005cites this paper
• Thyroid cancer imaging.

  2004cites this paper
• Chirurgie der Schilddrüsenkarzinome

  2004cites this paper
• In Vivo Imaging of Retinoic Acid Receptor Activity using a Sodium/Iodide Symporter and Luciferase Dual Imaging Reporter Gene

  2004cites this paper
• The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors

  2004cites this paper
• Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma

  2004cites this paper
• Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin.

  2004cites this paper
• TIMP1 and SERPIN‐A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma

  2004cites this paper
• Retinoid X receptor-; and peroxisome proliferator-activated receptor-; expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment

  2004cites this paper
• Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids.

  2004cites this paper
• Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment.

  2004cites this paper
• Treatment of Anaplastic Thyroid Carcinoma: A Therapeutic Dilemma

  2004cites this paper
• Mastopathy, breast cancer and iodolactone

  2004cites this paper
• The Management of Metastatic Differentiated Thyroid Carcinoma

  2004cites this paper
• Einfluß der Redifferenzierungstherapie mit Retinoiden auf Tumorwachstum und Tumorangiogenese bei Schilddrüsenkarzinomzellinien in vitro und in vivo

  2004cites this paper
• Rak pęcherzykowy tarczycy z przerzutami odległymi — opis przypadku

  2004cites this paper
• Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses.

  2004cites this paper
• Mastopathie, Mammakarzinom und Jodlactone

  2004cites this paper